HRTX News and Press, Heron Therapeutics Inc. From 02/22/23

Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital PR Newswire Appoints Three New Independent Directors SAN DIEGO , Feb. 22, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

The shares of Heron Therapeutics ( NASDAQ: HRTX ) added ~14% in the morning hours Monday after the New York-based hedge fund Rubric Capital Management reported 9.9% ownership in the biotech, representing approximately 11.8M shares. San Diego, California-based Heron ( HRTX ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises PR Newswire - Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 - - Preliminary Fourth-Quart...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Heron Therapeutics ( NASDAQ: HRTX ) added ~10% in the morning hours Thursday after announcing that the company submitted a supplemental New Drug Application ((sNDA) to the FDA seeking label expansion for its pain therapy Zynrelef. A combination of a non-steroidal anti-inflammatory dru...

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF PR Newswire - Supplemental New Drug Application...

Summary With two established FDA-approved therapies, Heron has a significant base of recurring revenues. Heron is working to get its third approved therapy onto an acceptable performance track. Heron's fourth approved therapy will be launching in Q1, 2023. Despite its approved t...